Clinical Trials
Sarepta doses first patient in eteplirsen trial to treat duchenne muscular dystrophy
US-based Sarepta Therapeutics has started dosing patients in a clinical trial of its lead exon-skipping therapeutic candidate eteplirsen to treat Duchenne muscular dystrophy (DMD). The open-label trial (Study 204) will be carried out in DMD patients...
Clinical Trials
TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative,...
Clinical Trials
FDA Approves Addition to CIALIS® (tadalafil) Product Label
Eli Lilly and Company announced the U.S. FDA approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in combination with finasteride significantly improved the...
Clinical Trials
The Netherlands-based company Prosena has begun the submission process for drisapersen, its treatment for Duchenne muscular dystrophy (DMD).
The news is a remarkable turnaround for the drug, which had looked doomed to failure just a few months ago. In January this year, GlaxoSmithKline returned the rights to the drug following failure in Phase 3 trials. ...
Clinical Trials
Oramed recruits patients to study orally ingestible insulin capsule
Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel. The company is also conducting ORMD-0801 US...
Clinical Trials
DiaMedica completes enrollment in DM199 single ascending dose diabetes study
Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study. The randomized study is designed to assess three dose levels each in type...
Clinical Trials
Eli Lilly reports positive data from Phase III study of Cialis
Eli Lilly and Company has reported positive data from the Phase III study of Cialis/finasteride in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates. According to the study,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
